Cost Effectiveness Analysis Trastuzumab Deruxtecan Versus Trastuzumab Emtansine Pada Pasien Kanker Payudara Metastatik Her2-Positif: Systematic Review

Juan Balapradhana Santoso

doi:10.55227/ijhet.v4i6.649

Authors

Juan Balapradhana Santoso S1 Kesehatan Masyarakat

DOI:

https://doi.org/10.55227/ijhet.v4i6.649

Abstract

HER2-positive breast cancer is one of the subtypes of breast cancer with a poor prognosis and a strong need for effective targeted therapies. Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are two antibody-drug conjugates (ADCs) used as second-line treatments for patients with this condition. To evaluate the cost-effectiveness between T-DXd and T- DM1 through a systematic review of relevant literature. Literature search was conducted using Scopus, PubMed, Science Direct, and Google Scholar databases with the keywords “cost effectiveness analysis” AND “metastatic breast cancer” OR “HER2-positive breast cancer” AND “trastuzumab deruxtecan” AND “trastuzumab emtansine”. A total of 521 articles were identified, but only 4 met the inclusion criteria. T-DXd was considered more cost-effective in high- income countries such as the United States (ICER as low as $13,342/QALY) and Finland (ICER approximately €55,360/QALY), but not in China, where the ICER reached $186,017/QALY,

Downloads

Download data is not yet available.

References

Hamilton, E. P., Bragaia, V. P. H., Yeo, W., Kim, S., Bianchini, G., Yamashita, T., Yonemori, K., Inoue, K., Curigliano, G., Hurvitz, S. A., Cortes, J., Iwata, H., Cathcart, J., Liu, Y., Lee, C. C., Bako, E., Kim, R., & Im, S. (2022). Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. Journal of Clinical Oncology, 40(16_suppl), 1000. https://doi.org/10.1200/jco.2022.40.16_suppl.1000

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022 Jan;25(1):3-9. doi: 10.1016/j.jval.2021.11.1351. PMID: 35031096.

Hurvitz, S., Kim, S., Chung, W., Im, S., Park,Y., Hegg, R., Kim, M., Tseng, L., Petry, V., Chung, C., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Egorov, A., Liu, Y., Cathcart, J., Bako, E., Tecson, K., . . Cortés, J. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open, 9(5),102924. https://doi.org/10.1016/j.esmoop.2024. 102924

Mudumba, R., Chan, H., Cheng, Y., Wang, C., Correia, L., Ballreich, J., & Levy, J. (2023). Cost-Effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Value in Health, 27(2), 153–163.

https://doi.org/10.1016/j.jval.2023.11.0 04

Paulissen, J. H. J., Seddik, A. H., Dunton, K. J., Livings, C. J., Van Hulst, M., Postma, M. J., De Jong, L. A., & Freriks, R. D. (2023). Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland. The European Journal of Health Economics, 25(4), 689–699.

https://doi.org/10.1007/s10198-023- 01617-3

Paramita, M. V. A. (2025). Keterlibatan Orang Tua dalam Pengenalan Sains Sederhana di Rumah: Systematic Literature Review: Penelitian. Jurnal Pengabdian Masyarakat dan Riset Pendidikan, 3(4), 2549-2558.

Yaghoubi, N., Fatemi, B., Ahmadi, R., Metghalchi, Y., Shahrami, B., Vaezi, M., & Rezaei, S. (2025). Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience. BMC Health Services Research, 25(1). https://doi.org/10.1186/s12913-025- 12876-6

Zhu, Y., Liu, K., Wang, M., Wang, K., & Zhu, H. (2022). Trastuzumab deruxtecan versus trastuzumab emtansineor patients with human epidermal growth factor receptor 2-positive metastatic breastcancer: A cost-effectiveness analysis. The Breast, 66, 191–198. https://doi.org/10.1016/j.breast.2022.1 0.010